COMPOSITIONS AND METHODS FOR ADMINISTERING GDNF LIGAND FAMILY PROTEINS

• US 20100056440A1
• Filed: 02/27/2007
• Published: 03/04/2010
• Est. Priority Date: 03/01/2006
• Status: Abandoned Application

• Current Assignee: Gloriana Therapeutics, Inc.
• Original Assignee: Biogen Idec MA Inc. (Biogen, Inc.)
• Inventors: Rossomando, Anthony, Pepinsky, R. Blake
• Application Number:
  US12/281,077
• Publication Number:
  US 20100056440A1
• Time in Patent Office: Days
• US Class Current: 514/1.100
• CPC Class Codes: A61K 38/185 Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
• CPC Class Codes: A61P 25/02 for peripheral neuropathies

Abstract

Disclosed are methods of increasing serum exposure of an administered glial cell line-derived neurotrophic factor (GDNF) ligand family protein by administering to a subject via systemic delivery (i) a GDNF ligand family protein, and (ii) an amount of heparin or heparan sulphate that increases serum exposure of the administered GDNF ligand family protein in the subject.

Claims

1. A method of increasing serum exposure of an administered glial cell line-derived neurotrophic factor (GDNF) ligand family protein, the method comprising administering to a subject via systemic delivery a pharmaceutical composition comprising (i) a GDNF ligand family protein, and (ii) an amount of heparin or heparan sulphate that increases serum exposure of the administered GDNF ligand family protein in the subject.

2. The method of claim 1, wherein the GDNF ligand family protein is a Neublastin polypeptide.

3. The method of claim 1, wherein the GDNF ligand family protein is a GDNF polypeptide.

4. The method of claim 1, wherein the GDNF ligand family protein is a Neurturin polypeptide.

5. The method of claim 1, wherein the GDNF ligand family protein is a Persephin polypeptide.

12. The method of claim 1, wherein the GDNF ligand family protein is not conjugated to a polymer.

13. The method of claim 1, wherein the systemic delivery is intravenous administration.

14. The method of claim 1, wherein the systemic delivery is subcutaneous administration.

6. A method of treating a nervous system disorder, the method comprising administering to a subject that has a nervous system disorder, via systemic delivery, an effective amount of a pharmaceutical composition comprising (i) a GDNF ligand family protein, and (ii) an amount of heparin or heparan sulphate that increases serum exposure of the administered GDNF ligand family protein in the subject.

7. The method of claim 6, wherein the GDNF ligand family protein is a Neublastin polypeptide.

8. The method of claim 6, wherein the GDNF ligand family protein is a GDNF polypeptide.

9. The method of claim 6, wherein the GDNF ligand family protein is a Neurturin polypeptide.

10. The method of claim 6, wherein the GDNF ligand family protein is a Persephin polypeptide.

11. The method of claim 6, wherein the nervous system disorder is neuropathic pain or loss of pain sensitivity associated with a neuropathy.